Ozempic-maker Novo Nordisk sues Eli Lilly over misleading obesity drug ads

Danish pharmaceutical giant Novo Nordisk has launched legal action against US rival Eli Lilly, accusing it of running "misleading" advertising for its obesity drugs. Eli Lilly has denied the allegations. The lawsuit reflects intensifying competition between the two companies in the fast-growing GLP-1 drug market.